Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Pediatr Blood Cancer. 2018 Nov;65(11):e27293. doi: 10.1002/pbc.27293. Epub 2018 Jul 3.
Hepatocellular carcinoma (HCC) is an aggressive malignant neoplasm that is often chemoresistant. Complete surgical resection remains the mainstay of therapy. The role of liver transplantation (LT) in pediatric HCC is in evolution, as is the role of adjuvant chemotherapy for stage I disease.
A retrospective review of patients < 18 years of age with completely resected HCC treated with surgical intervention alone at our institution from 2004 to 2015 was conducted.
Twelve patients with a median age of 12 years (range = 1-17; number of females = 7) with upfront resected HCC (Evans stage I) were identified. Four patients had HCC without identifiable risk factors (fibrolamellar-HCC = 2; early HCC arising in focal nodular hyperplasia = 1, well-differentiated [wd] HCC = 1). Four patients had early or wd-HCC in the context of portosystemic shunts (Abernethy = 2; mesocaval shunt and portal vein thrombosis = 2). Four patients had moderate to wd-HCC in the context of pre-existing liver disease with cirrhosis (progressive familial intrahepatic cholestasis type-2 = 2, alpha-1 antitrypsin deficiency = 1, Alagille syndrome = 1). Seven patients underwent LT (multifocal = 5; solitary = 2); five exceeded Milan criteria (MC) by imaging. Five patients underwent complete resection (segmentectomy = 2; hemihepatectomy = 3). Ten patients received no adjuvant chemotherapy. All patients are alive without evidence of disease with a median follow-up of 54.1 months (range = 28.1-157.7 months).
Pediatric and adolescent patients with upfront, completely resected HCC can be effectively treated without chemotherapy. LT should be considered for nonmetastatic HCC, especially in the context of pre-existing chronic liver disease, even when the tumor exceeds MC. Distinct pediatric selection criteria are needed to identify patients most suitable for LT.
肝细胞癌(HCC)是一种侵袭性恶性肿瘤,通常对化疗有耐药性。完全手术切除仍然是主要的治疗方法。肝移植(LT)在儿科 HCC 中的作用正在不断发展,I 期疾病的辅助化疗作用也是如此。
对 2004 年至 2015 年在我院接受单独手术干预完全切除 HCC 的<18 岁患者进行回顾性分析。
确定了 12 名中位年龄为 12 岁(范围 1-17;女性 7 名)的患有 HCC 并接受手术治疗的患者(Evans 分期 I)。4 名患者的 HCC 没有可识别的危险因素(纤维板层 HCC 2 例;早发 HCC 发生于局灶性结节性增生 1 例,高分化[wd]HCC 1 例)。4 名患者因门腔分流术(Abernethy 分流术 2 例,门腔分流术伴门静脉血栓形成 2 例)而患有早发或 wd-HCC。4 名患者因伴有肝硬化的原有肝脏疾病而患有中重度 wd-HCC(进行性家族性肝内胆汁淤积症 2 型 2 例,α-1 抗胰蛋白酶缺乏症 1 例,Alagille 综合征 1 例)。7 名患者接受了 LT(多灶性 5 例,单发 2 例);5 例患者的影像学超出了米兰标准(MC)。5 名患者接受了完全切除术(节段切除术 2 例,半肝切除术 3 例)。10 名患者未接受辅助化疗。所有患者均无疾病证据,中位随访时间为 54.1 个月(范围 28.1-157.7 个月)。
对于没有化疗的初发、完全切除的 HCC 患儿和青少年患者,可以有效治疗。LT 应考虑用于非转移性 HCC,特别是在存在原有慢性肝病的情况下,即使肿瘤超过 MC。需要明确的儿科选择标准来确定最适合 LT 的患者。